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Abstract
During the past decade, a substantial increase in the use of second generation antipsychotics (SGAs) has occurred
for a number of juvenile psychiatric disorders, often as off-label prescriptions. Although they were thought to be
safer than older, first generation antipsychotics, mainly due to a lower risk of neurological adverse reactions, recent
studies have raised significant concerns regarding their safety regarding metabolic, endocrinological and cardiovascular
side effects. Aim of this paper is to update with a narrative review, the latest findings on safety of SGAs in
youths. Results suggest that different SGAs may present different safety profiles. Metabolic adverse events are
the most frequent and troublesome, with increasing evidences of heightened risk for type II diabetes mellitus.
Results are discussed with specific emphasis on possible strategies of an active monitoring, which could enable both
paediatricians and child psychiatrists to a possible prevention, early detection, and a timely management of such effects.
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Background
During the past decade, a substantial increase has
occurred in the use of second generation antipsychotics
(SGAs) for a number of psychiatric disorders in paediat-
ric patients [1, 2]; the phenomenon is worldwide,
although its magnitude varies a lot among countries. For
example, in Europe and particularly in Italy the increase
is much lower than in the United States (U.S.) [3, 4].
SGAs are prescribed both as in- or off-label medications
for various conditions, such as schizophrenia spectrum
disorders, irritability and aggression in autism spectrum
disorder or intellectual disability, tics or Tourette’s Dis-
order, mood disorders (mainly bipolar), conduct disor-
ders and eating disorders [2, 5–9]. Polypharmacy with
more than one SGA and with other psychotropic drugs
is also common (about one third, in U.S. samples) [4, 5].
Clozapine was the first SGA to be released, and there-
after Risperidone, Olanzapine, Quetiapine, Aripiprazole,
Ziprasidone, Paliperidone and Asenapine have followed.
Second generation antipsychotics block D2 dopamine
receptors, similarly to first generation antipsychotics
(FGAs), but with lower receptor occupancy. In addition,
they block serotonin receptors in the cortico-limbic
pathways. For this reason, they were thought to be safer
than FGAs (e.g. Haloperidol), mainly due to a better
neurological profile [10, 11], although recent studies
have raised significant concerns regarding their adverse
events related to the metabolic syndrome (weight gain/
obesity, hypercholesterolemia, hypertriglyceridemia, hyper-
lipidemia, hyperglycemia/hyperinsulinism, hypertension)
[12–14]. These adverse effects are more frequent in youths
than in adults, probably due to less prior SGAs exposure
[12, 15]. Other adverse effects were reported, such as
hyperprolactinemia, cardiovascular-related events (e.g. car-
diac arrhythmias, prolonged QT interval, and orthostatic
hypotension), and neurological disturbances (acute and
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tardive dystonia, neuroleptic malignant syndrome, Creatine
Kinase elevation) [16]. In 2011, recommendations for
paediatric SGAs use were published by both the AACAP
(American Academy of Child and Adolescent Psychiatry
2011) and the Canadian Alliance for Monitoring Effective-
ness and Safety of Antipsychotics in Children (CAMESA)
[17, 18]. Each recommendation focuses on a combination
of different baseline and periodic monitoring of: 1) patient
history and physical examination; 2) measurement of
height, body weight, or body mass index (BMI); 3) blood
pressure; 4) fasting plasma glucose and metabolic variables;
and 5) potential, precautionary inclusion of an electrocar-
diogram (ECG) to identify QTc prolongation [[17, 18]; see
also [19] for a summary]. Despite the growing awareness
and evidence-based data regarding SGAs safety issues in
youth, national monitoring programs are still lacking, and
mental health professionals do not seem to adhere cor-
rectly to current guidelines [19–21]. Adverse events from
therapeutically-intentioned use of antipsychotics still cause
thousands of child and adolescents’ emergency department
visits annually in the U.S., with significantly higher risk
compared to other psychotropic medications, such as stim-
ulants or antidepressants [22]. Despite these concerns,
inconsistent monitoring patterns are reported for children
assuming SGAs. Rodday et al. [19] found that two thirds of
clinicians report a careful assessment of patient history,
height and weight, blood pressure, fasting plasma lipids
and glucose, but only 23 % report a regular monitoring of
waist circumference, and only 12 % monitor cardiac func-
tioning with an electrocardiogram. This is consistent with
a study by Connolly et al., according to which insufficient
rates of metabolic screening tests are performed, mainly
blood glucose level [21].
Aim of this review is to update the evidence on the
safety of SGAs in paediatric patients, with specific focus
on those that can be prevented, managed or at least
blunted with a careful monitoring. This review analyses
relevant papers (mainly large prospective and retrospective
cohort studies) published from January 2011 to January
2016, after the release of the two guidelines from AACAP
and CAMESA. In the text, we will highlight the nature of
the study (RCT = randomized controlled trial, ES = epi-
demiological studies, OS = observational studies), to im-
prove readability. It is important to underline that RCTs
may not be powered/appropriate to detect rare or late-
onset adverse effects, as compared to large cohort and/or
long term observational studies. Results are reported in a
qualitative manner, rather than systematically.
SGAs and weight gain
Since the issuing of guidelines on monitoring and man-
agement of antipsychotic-related weight gain [17, 18],
more recent studies [23–26] confirmed previous findings
[9–12, 27, 28] regarding the different risk with different
SGAs. The risk seems higher for Olanzapine and
Clozapine, medium for Risperidone, and lower for
Quetiapine, Aripiprazole and Ziprasidone [12, 25, 29, 30].
A Dutch study assessed cross-sectionally and, for a subset
of patients, longitudinally, children receiving SGAs (82 %
Risperidone), for a mean 6-month follow-up (OS) [31].
Compared to a control sample of untreated children,
patients receiving SGAs presented significant overweight
and obesity (OR = 3.1 and 3.6, respectively), and signifi-
cant SGA-dependent increase in weight-z (+0.77 vs. -0.1)
and BMI-z (+0.8 vs. +0.05) measures. Another study, with
a 4-month follow-up, showed a greater weight increase
with Risperidone, as compared to FGAs (+3.7 kg vs. + 0.9
Kg), and +13 kg and +4 BMI-z, with respect to untreated
subjects, irrespective of drug exposure time (OS) [32]. A
relevant study of 4280 adults and 179 adolescents,
followed for up to 6 months, investigated the effect of age
on Olanzapine-dependent weight gain [33]. The risk
was markedly higher in the adolescents, with an aver-
age of +11.2 vs. +4.8 Kg and 89 vs. 55 % patients
with clinically relevant weight increases, as compared
to adults (OS). Short-term effects were investigated in
several randomized controlled trials. In a sample of
bipolar adolescents receiving Risperidone, body weight
increase was two-fold that with Valproic Acid, while
BMI increased 3.5-fold after 1 month of treatment
(RCT) [34]. Olanzapine treatment for 1.5 months in-
creased weight by 4.2 Kg, compared to placebo, with
31 % patients presenting a relevant weight gain
(>7 %) (RCT) [35]. In patients with irritability in the
context of Autism Spectrum Disorder receiving Aripi-
prazole for 2 months, weight increase significantly
(0.9 mean Kg in those with prior exposure to antipsy-
chotics, 1.2 mean Kg in naïve ones) and relative risk
(the ratio of the probability of an event occurring in
an exposed group divided by the probability of the
event occurring in a comparison, non-exposed group)
of a clinically relevant weight gain was 4.6 as compared to
placebo users, with drug-naïve patients (82 %) presenting
the highest risk (post hoc analysis of two RCTs) [36].
Regarding Quetiapine, a first study (RCT) [37] reported a
detrimental effect after 1 month of therapy, in terms of
weight gain (+1.8 to +2.2 Kg), number of patients with
relevant weight gain (+11 to +16 %), and increased BMI z-
score (+0.2 to +0.3). In the continuation study (4-month
follow-up) (OS), 18 % of the study population experi-
enced significant weight gain [38]. A relevant study
including only drug-naive patients with mixed diagnoses,
treated with Risperidone, Olanzapine and Quetiapine, and
followed-up for 6 months, showed that all treatments
were associated with an increase of all body measures
(weight, BMI, waist circumference) (OS) [23]. More spe-
cifically, children of normal weight decreased from 84.5 to
64.4 % (prevalently with Risperidone and Olanzapine),
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while obese children increased from 5 to 8.6 %. In a com-
parison among the three SGAs, Olanzapine led to the
greatest weight gain, compared to Risperidone (at 3 and
6 months) and Quetiapine (at 6 months), with dose-
dependency found for Risperidone and Quetiapine. Dose-
dependency was not found in another 7-months study on
schizophrenic children and adolescents, investigating
Risperidone, Quetiapine and Olanzapine (OS) [39]. No
differences among SGAs emerged, with an overall BMI in-
crease of 1.5, and 38 % patients with clinically relevant
weight gain. An 18-months study on Risperidone evalu-
ated the effects of maintenance vs. discontinuation vs.
SGA switch (OS) [40]. Compared to patients who contin-
ued Risperidone, neither those who discontinued, nor
those who switched to other SGAs (a small subsample of
very different drugs) decreased their BMI, body fat mass,
waist circumference, and prevalence of obesity [40]. A 24-
months observation of psychotic adolescents, treated
predominantly with Risperidone, Olanzapine and Que-
tiapine, demonstrated a greater increase in BMI and
BMI z-score among those receiving Olanzapine (+4.3
and 1.3 vs. +2.5 and 0.7 with Quetiapine, and. +1.8
and +0.5 with Risperidone) at 6 months, while no dif-
ferences among SGAs were found at 24 months (OS)
[24]. A study with similar duration, comparing Risper-
idone and Aripiprazole in children and adolescents
with Autism Spectrum Disorder, found similar significant
increases for both drugs (+2.4 BMI and +0.5 BMI-z per
year with Risperidone, and +2.1 BMI and +0.6 BMI-z per
year with Aripiprazole) (OS) [41]. Another study on a
sample of patients with first psychotic episode (mean age
27 years) compared Olanzapine, Risperidone and the FGA
Haloperidol (OS) [42]. At the study end-point of
36 months, patients gained an average of 12 Kg, and 78 %
patients presented a clinically relevant weight gain, with
31 % having a BMI >30. Weight rapidly increased during
the first year of treatment (85 % of the total weight gain),
then prevalently stabilized over time. An association was
found between the use of Olanzapine and earlier weight
gain. Interestingly, at 36 months weight gain was associ-
ated with a positive psychiatric course [42].
SGAs and diabetes
The rapid weight gain and metabolic abnormalities
determined by SGAs have been associated with the
increased risk of Diabetes Mellitus type 2 (DM2) (for a
review see Galling et al. [43]). Moreover, Teff et al. demon-
strated that antipsychotics are associated with a post-
prandial insulin dysregulation, independently from weight
gain [44]. Such data were confirmed through large epi-
demiological studies [45, 46]. A retrospective cohort study
of the Tennessee Medicaid program compared 28,858
youths who started antipsychotics (87 % SGAs, 40 %
Risperidone) and 14,429 controls, who started other
drugs (mood stabilizers, stimulants, antidepressants,
α-stimulants and benzodiazepines) (ES) [47]. Data
showed that the first group had a 3-fold increased
risk to develop DM2; the risk increased significantly
with the increase of cumulative dose, and remained
high after 1 year from discontinuation. Results were
similar when the cohort was limited to children 6 to
17 years of age [47]. Another study by Shon et al.
reported similar results, with a more than 2-fold in-
creased risk to develop DM2 in antipsychotic users;
interestingly, the risk difference between those receiv-
ing and not receiving SGAs was evident after 4 to 6
months of treatment (ES) [48]. More recently, a U.S.
study focused on the incidence of DM2 in drug-naïve
SGA users (ES) [49]. The sample included 1,328,985
youths aged 10 to 18 years (107,551 assuming SGAs,
38.9 % Risperidone). The incidence of DM2 was 0.4
and 0.2 % respectively in SGA initiators (I) and non-
initiators (NI) (I: prevalence 38/10,000, NI: prevalence
25/10,000). Authors concluded that SGAs increased
the risk of DM2 (O.R. 1.51, C.I. 1.35–1.69, p< 0.001).
The mean time between the first SGA exposure and
DM2 diagnosis was 13.5 months (SD 9.2). Further-
more, the concomitant use of stimulants did not
reduce the risk, whereas the concurrent use of an
antidepressant further increased it. Authors showed
that, compared with Risperidone, newer antipsychotics
were not associated with a decreased risk [49]. In the
study by Arango et al., a significant increase in the
number of patients experiencing hyperglycaemia was
found in the Risperidone group, compared to other
SGAs (OS) [23]. A recent meta-analysis confirmed
that the cumulative risk and the incidence rate ratio
were significantly greater in antipsychotic-exposed
youth, compared to healthy and psychiatric controls,
with Olanzapine presenting the greater cumulative risk
[50]. From another perspective, Galler et al. explored
glycaemic and metabolic control in youths with type 1
diabetes with and without antipsychotics. They found a
higher HbA1c level among SGAs users (ES) [51].
SGAs and dyslipidemia
SGA use can lead to dyslipidemia [25, 29, 52]. Triglycer-
ides and cholesterol increase occurs early, and may even
precede weight gain, showing an independent molecular
effect, in addition to the weight related-effect [25]. A
study including adolescent and adult patients with firsts
psychotic episode receiving Olanzapine, Risperidone and
the FGA Haloperidol (OS) [42] found weight, cholesterol
and trygliceride levels rapidly increased during the first
year of treatment (85 % of the total weight gain), then
prevalently stabilized over time. In the study by Arango
et al. (OS) [23], Risperidone was associated with an in-
crease in triglycerides, and Olanzapine with an increase
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in total cholesterol and low-density lipoproteins. In this
study, Quetiapine showed no impact on triglycerides
and cholesterol, but other studies reported an increase
of such parameters [30, 39]. Aripiprazole and Ziprasi-
done seem to cause dyslipidaemia less than other SGAs,
but data are far from being conclusive [53].
SGAs and prolactin
The dopamine blockade on the anterior lobe of the pitu-
itary gland due to SGAs is often associated with hyper-
prolactinemia. Raises in prolactin (PRL) levels may cause
gynecomastia, galactorrhea, irregular menses, and amen-
orrhea in women, sexual dysfunction (decreased sexual
desire, erectile-ejaculatory dysfunction, orgasmic dys-
function, vaginal dryness), and reduced fertility [54]. The
induced hypogonadotropic hypogonadism, together with
low oestrogen and testosterone levels, may lower bone
mineral density, and cause osteoporosis [55]. Children
and adolescence are at higher risk for hyperprolactine-
mia, probably due to an age-related decrease in dopa-
mine receptors [14, 54, 55]. Risperidone and, to a lesser
extent, Olanzapine and Ziprasidone, appear to have the
largest propensity for prolactin elevation, while Quetia-
pine and Clozapine seem to be neutral as regards PRL
levels [26, 30, 55, 56], and Aripiprazole often lower PRL
levels, due to its partial dopamine agonism [57]. Regard-
ing Risperidone, a meta-analysis by Pringsheim et al.
[29] found significant increases in PRL levels from base-
line to endpoint in Risperidone-treated compared to
placebo-treated children, with a mean difference of
44.57 ng/ml (p< 0.00001). Another study revealed hyper-
prolactinemia during Risperidone treatment in up to
65.8 % of patients, usually without signs or symptoms
[57]. The rise in PRL is dose-dependent, and usually oc-
curs in the first 4–8 weeks of treatment [55]. In a recent
comparative trial between Risperidone and Quetiapine,
the latter showed a less pronounced effect on prolactin
levels (RCT) [58]. Less is known on the long-term con-
sequences of hyperprolactinemia. Based on data of two
studies with 1-year follow-up [59, 60], hyperprolactine-
mia seems not to affect growth and sexual maturation,
but to increase the risk for gynecomastia (at least re-
garding Risperidone) [61]. Although it cannot be totally
ruled out, the causal relationship between prolactin-
raising antipsychotics and prolactinomas is still missing
[25]. Regarding Aripiprazole, it resulted to induce a
marked reduction of prolactin levels. In a study by Safer
et al., 60 % of those treated with Aripiprazole showed
suboptimal prolactin levels as compared to 8 % of un-
medicated subjects. The prolactin decrease was found to
be more prominent with higher doses and longer treat-
ment durations (OS) [62]. The effect of prolonged low
prolactin levels on brain and physical development is
mostly unknown and warrant future studies.
SGAs and cardiovascular safety
Electrocardiogram (ECG) abnormalities and arrhythmias
-Torsades des pointes (TdP) have been reported in
patients on FGAs and SGAs [63, 64]. An absolute QTc
interval of >450 ms or an increase of 60 ms from base-
line are often used as threshold requiring clinical atten-
tion [65, 66], but arrhythmias are most often associated
with values of 500 ms or more [53]. Intervals of 440 to
460 ms in men and 440 to 470 ms in women are consid-
ered borderline [67]. However, evidences to support a
causal pathway from antipsychotics use to QTc pro-
longation and risk of TdP and sudden death are less
conclusive [53, 68]. QTc prolongation is partly dose-
related, although a genetic disposition may contribute to
antipsychotic-induced arrhythmogenesis, as up to 10 %
of individuals developing TdP presents mutations associ-
ated with the congenital long-QT syndrome [68]. Signals
for QTc prolongation have been detected in a large data-
base study for Risperidone and Ziprasidone (ES) [64].
Correll et al. (OS) [69] measured the frequency of base-
line prolongation of QTc in 811 psychiatric paediatric
inpatients. QTc duration was 440 ms or greater (range
441–481 ms) in 16 patients (1.97 %). Compared with
patients with normal QTc, similar rates of utilization of
antipsychotics (43.8 vs. 40.8 %) and daily chlorpromazine
equivalent doses (165 ± 110 vs. 168 ± 218 mg) were
found in patients with prolonged QTc, while a correl-
ation was found between obesity and QTc prolongation.
Germanò et al. (OS) [70] assessed the arrhythmogenic
risk of Risperidone and Aripiprazole in paediatric pa-
tients. Despite a small increase in mean QTc in Risperi-
done group, no clinically meaningful effects were found
for both drugs. Ho and colleagues found no significant
cardiac effect of Aripiprazole in patients with autism
spectrum disorder treated for irritability for up to
14 weeks (OS) [71]. Gulisano et al. assessed the cardio-
vascular safety of Aripiprazole compared to the FGA
Pimozide. At the end of the 24 months observation
period, they found no effect on cardiac conduction for
Aripiprazole, whereas Pimozide significantly increased
the QTc interval (OS) [72]. More recently, Jansen et al.
[66] performed a meta-analysis on QTc changes during
antipsychotic treatment, including randomized and open
label clinical trials. This meta-analysis included 5,423 pa-
tients with QTc data (mean age 12.8 ± 3.6 years, 32.1 %
of female). Within group, from baseline to endpoint,
Aripiprazole significantly decreased the QTc interval by
1.44 ms, whereas a modest increase was found with
Risperidone (+1,69 ms, CI = +0,67 to +2,60, p = 0.001)
and especially with Ziprasidone (+8,74 ms, CI = +5,19 to
+12,3, p = 0.001). However, compared to pooled placebo,
none of the investigated antipsychotics caused a signifi-
cant increase of the incidence of QTc prolongation.
These findings are substantially consistent with findings
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from adults [73]. A recent study including 216 paediatric
patients on Olanzapine, Quetiapine and Risperidone,
followed-up for 12 months, failed to report increases in
QTc or in heart rate; moreover, there were no QTc
values >500 ms at any of the time assessments (OS) [74].
Ziprasidone was found to be associated with a significant
prolongation of QTc, but not QTc dispersion, in a dose-
and level-independent way, in a quarter of youth in a
longitudinal study of 29 patients (OS) [75]. Based on
these data, the risk of pathological QTc prolongation
seems low during treatment in healthy youth. Neverthe-
less, because individual risk factors interact with
medication-related QTc effects, a careful assessment of
both medication and patient factors need to be consid-
ered when choosing the antipsychotic treatment.
Another possible cardiac adverse event during anti-
psychotic treatment is myocarditis. It has been described
mainly for Clozapine in adults with a frequency up to
3 %; data on youths are lacking, but awareness and cau-
tion are required, namely in long-term treatments [76].
SGAs and neuromotor adverse effects
Movement disorders, namely extrapyramidal symptoms
(EPS) were historically the most common antipsychotic
adverse effects leading to an emergency department visit.
SGAs have been considered at lower risk of EPS, as
compared to FGAs. However, the risk is not absent, and
children and adolescents seem more sensitive than
adults to EPS [11, 16, 29]. These effects include chronic
or acute dystonia (sustained involuntary muscle contrac-
tions causing twisting and repetitive movements or abnor-
mal postures), parkinsonism (rigidity, tremor, bradykinesia
and postural instability), akathisia (a sense of inner unease,
manifested by an inability to sit still and a need to move
around), and tardive dyskinesia (chronic and persistent
abnormal movements such as grimacing, tongue move-
ments, lip smacking, pursing of the lips, excessive eye
blinking, rapid and involuntary movements of the limbs,
torso, and fingers) [68]. A systematic review and meta-
analysis of randomized controlled trials demonstrated
a higher risk of EPS for Risperidone, Aripiprazole and
Olanzapine, as compared to placebo, whereas Quetia-
pine and Clozapine seem to be more neutral in this
regard [29].
Recently, Carbon et a l. reported the incidence rate of
EPS in a large cohort of paediatric patients followed for
up to 3 months (OS) [77]. A relatively low incidence of
drug-related Parkinsonism (15.2 %) was found, with the
highest rate for Aripiprazole (27.2 %), and lowest for
Quetiapine (1.5 %). The overall 3-month incidence rate
of treatment emergent dyskinesia was 8.28 %, ranging
from 4.41 % for Risperidone to 26.6 % for Ziprasidone.
The overall 3-month incidence rate of akathisia was
4.8 % without differences among SGAs. In multivariate
analyses, a significant effect of drug type was detected
for Quetiapine and Olanzapine (low EPS liability) and
Ziprasidone (high EPS liability). Drug-induced Parkin-
sonism was associated with higher doses, older age, and
lower baseline functioning, while titration rate was
debated as a possible triggering factor. Also polyphar-
macy has been associated with increased rate of tremor
and dyskinesia [77]. Neurological adverse events of
Risperidone, Quetiapine and Olanzapine were explored
in a sample of 256 subjects naturalistically treated over a
time span of 1 year (OS) [78]. Risperidone presented
higher scores in dyskinesia and Parkinsonism, while
Quetiapine was associated with less neurological adverse
events. Younger age, psychotic symptoms and higher
cumulative exposure time all increased the risk for tard-
ive dyskinesia.
SGAs and neuroleptic malignant syndrome
A rare, severe adverse reaction associated with anti-
psychotic treatment is neuroleptic malignant syndrome
(NMS), characterized by muscular rigidity, hyperthermia,
autonomic dysfunction, alterations of mental status,
myonecrosis, leukocytosis and elevated blood CPK [79].
As recently reviewed, SGAs may cause NMS as well as
FGAs, but with lower incidence, lower clinical severity,
and more rare fatal outcomes [79]. Findings are similar
in children and adolescents. In a case series of 23 NMS
cases, the time of onset ranged from immediately to
56 days (mean 8.7 ± 16.2 days), and subjects were pre-
dominantly males, and no one of the cases resulted in
death or permanent sequelae [80]. Signal detection for
NMS was found for Aripiprazole in a database study
(ES) [64]. Masi et al. reported on a particular condition
that may occur during SGA treatment, named MACKE
(Massive Asymptomatic Creatine Kinase Elevation).
MACKE is an isolated asymptomatic elevation of CK,
not explained by other neurological or medical condi-
tions or environmental events, without other signs of
NMS. They suggest that the “real” MACKE undergoes
spontaneous remission, and does not represent a pro-
drome of NMS or rhabdomyolysis. However, in case of a
random finding of CK elevation, close monitoring of the
patient is warranted [81].
Discussion
This review substantially supports the validity of existing
guidelines (see Tables 1 and 2) [17, 18]. However, it is
important to highlight some relevant new evidences.
The main finding of this study is that metabolic adverse
effects and heightened risk for type II diabetes mellitus
are the most frequent and troublesome. Usually, a
weight gain of >7 % from the baseline weight is consid-
ered clinically relevant [14, 29]. Although the weight
gain propensity of SGAs is renown, its extent is striking.
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Olanzapine and Clozapine seem to promote the highest
weight gain, followed by Risperidone, and then Aripipra-
zole, Quetiapine and Ziprasidone [14, 23, 25]. As differ-
ent time patterns of weight gain between SGAs have
been demonstrated, clinicians should carefully consider
the timing of monitoring [23]. Weight markedly in-
creases during the first 3 months of treatment with all
drugs, and thus, whatever drug is used, the monitoring
should be frequent and rigorous in this phase. Subse-
quently (3–6 months of treatment), the magnitude of
weight gain may tend to decline as compared to the first
3 months with Olanzapine and Risperidone, whereas no
further increase should occur with Quetiapine [23].
However, long term data from adults do not indicate
typical antipsychotics as safer [82]. Prevalence of a full
metabolic syndrome in children and adolescents on
SGAs is low [12, 14], but given the paucity of long-term
data, we cannot rule out a cascade of events leading
from weight gain to full blown of metabolic syndrome.
Unfortunately, data on diabetes seem to support this no-
tion [47–50]. The three-fold increased risk for diabetes
in SGA users is troublesome, and preliminary data on
dyslipidaemia are not reassuring as well. Consistent with
guidelines and some recent reviews [43, 83], we strongly
advise a baseline and routine glycaemic and lipid profil-
ing to timely detect patients at risk for type II diabetes
or metabolic syndrome. This is even more important in
case of a family history of diabetes, dyslipidaemia and
obesity, or in case of weight gain. Overall, prevention
and treatment of metabolic symptoms during SGAs
exposure are still unmet needs, especially in youths.
Psychoeducational and physical programs have been de-
veloped, but data come from adult populations, and
these findings still lack translation from research to the
clinical practice, or from adult to young populations
(cost effectiveness, adherence, etc. should be verified)
[84]. Switching to an antipsychotic with lower propensity
for weight gain seems to be a good strategy to blunt the
metabolic effects, but no randomized trials have yet been
conducted, and no SGA is absolutely free from meta-
bolic consequences. Metformin seems to be a promising
agent to reduce glucose intolerance, and even weight
gain, but data on paediatric populations are still scant
[85]. A placebo-controlled trial in children on SGAs re-
ported Metformin to be safe and effective in abrogating
weight gain; it decreased insulin sensitivity and abnormal
glucose metabolism [86]. Few placebo-controlled studies
have explored the positive effect of add-on melatonin in
mitigating metabolic side-effects of antipsychotic drugs
[87, 88]. Regarding adolescents aged 11 to 18 years,
Mostafavi et al. compared 24 bipolar youths receiving
olanzapine, lithium carbonate and melatonin, and 24 re-
ceiving olanzapine, lithium carbonate and placebo, and
melatonin significantly inhibited the rise in total choles-
terol levels compared to placebo, while fasting blood
sugar and triglyceride showed greater increase in the
placebo group, but the differences were not statistically
significant [89]. Finally, a single case report suggested
that Omega-3 fatty acid supplementation may limit
triglycerides and cholesterol increases [52].
Regarding EPS, Carbon et al. explored possible differ-
ences between SGAs (lowest risk for Olanzapine and
Quetiapine, highest risk for Ziprasidone), and warned
about polypharmacy and improper high doses [77].
Consistently, Garcia-Amador reported lowest risk for
Quetiapine, and highest for Risperidone. Whereas Car-
bon et al. deemed neuromotor events as not being a
major clinical problem, due to their relatively low preva-
lence and low severity, Garcia-Amador et al. warranted
caution (and active monitoring), and pointed out the
false belief about the neuromotor safety of SGAs.
Recent data provided new insights on QTc prolonga-
tion and cardiac safety [66–73]. Based on empirical evi-
dences, SGAs are relatively safe regarding cardiac
concerns, as QTc prolongation is a rare event [69, 74],
and its magnitude is often clinically irrelevant [66].
However, although baseline ECG is not required by both
guidelines (except for Ziprasidone) [17, 18], we suggest
that performing an ECG, if possible and feasible, may be
advisable after 3 months of treatment and every 6
months (mainly in case of higher doses, fastest titration,
concurrent medications or obesity). Furthermore, a care-
ful anamnestic interview, exploring possible individual
factors (personal or familial history of syncope, tachy/
Table 1 Summary of adverse events sorted by drugs
Adverse events Clozapine Olanzapine Risperidone Quetiapine Ziprasidone Aripiprazole
Weight gain ++ ++ + +/− +/− +
Diabetes ++ ++ + +/− +/− +
Dyslipidemia + ++ + +/− +/− +/−
Extrapyramidal symptoms − + ++ +/− ++ +
Cardiac effect (mainly Qtc prologation) + a +/− + +/− ++ +/−
Prolactin − +/− + − +/− − b
Legend: ++ highest propensity to cause the index adverse event. + propensity to cause the index adverse event. +/− slight propensity to cause the index adverse
event or inconsistent findings among papers. − neutral regarding the index adverse event. arisk for myocarditis. bpossible lowering effect
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Table 2 Suggested monitoring pattern and AEs management strategiesa
Time What to do Results Possible strategies
I Step General and neurological examination
(weight, waist circumference, blood
pressure…)
Normal Plan a careful and tailored monitoring
program/psychoeducation on drug side
effects/healthy lifestyle, including diet
and, when possible, exercise
Baseline Abnormal
Careful anamnestic interview about
personal and familiar history of:
Dyslipidemia, DM2, Obesity, Thyroid
dysfunction, Arrythmogenic risk
(sudden death, syncope, Prolonged
QTc, Brugada syndrome)
Negative History Regular monitoring




Blood examination for haemachrome,
liver function, glucose, insulin and
lipid profile, (thyroid function and
PRL if possible)




Careful and close monitoring/
psychoeducation/chose a SGA with
lower metabolic impact
ECG (in case of Ziprasidone or




QTc>450 msec or other
arrythmogenic signs
Discuss with paediatric cardiologist
about the cardiac safety and the
risk- benefit ratio in starting a SGA/if
possible chose another drug class
or a SGA with lower impact on QTc
II Step Weight and waist circumference
monitoring




Weight gain >7 % of
baseline weight
Careful and close monitoring/Healthy
lifestyle/Psychoeducation/if possible
switch to another SGA
Blood examination for haemachrome,
liver function, glucose, insulin and
lipid profile




Careful and close monitoring/Healthy
lifestyle interventions/Psychoeducation/
if possible switch to another SGA
PRL related symptoms (galactorrhea,
increased breasts volume, sexual
dysfunction…) monitoring
- symptoms Regular monitoring
+ symptoms Blood prolactin determination/if
possible lower the SGA dose/if possible
switch to another SGA/if possible add
Aripiprazole/discuss with paediatric
endocrinologist the possible add on
of a prolactin-lowering drug
(cabergoline or bromocriptine)
EPS and other neurological symptoms
monitoring
- EPS Regular monitoring
+ EPS If possible lower dose/if possible add
on anticholinergics or benzodiazepines
NMS symptoms Hospitalization
ECG (in case of Ziprasidone or positive









Discuss with paediatric cardiologist
about the cardiac safety and the
risk- benefit ratio in continuing a
SGA/possible SGA discontinuation
III Step Weight and waist circumference
monitoring
Weight gain <7 % of
baseline weight
Regular monitoring/healthy lifestyle
3-, 6- month and periodic
(every 6 months) Weight gain still
increasing
Careful and close monitoring/Healthy
lifestyle/Psychoeducation/if possible
switch to another SGA
Blood examination for haemachrome,
liver function, glucose, insulin and
lipid profile
Normal Regular monitoring/healthy lifestyle
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brady-cardia, palpitations etc.), and/or familial cases of
sudden death, prolonged QTc, Brugada syndrome, and
other arrhythmogenic conditions, is warranted. In these
conditions, irrespective of the SGA used, baseline and
follow-up ECGs are strictly advised after 1 month of
treatment and every 3 months (mainly in case of
higher doses, fastest titration, concurrent medications
or obesity). When QTc prolongation is greater than
450 ms, resting heart rate is >130 beats per minute,
the PR interval is >200 ms, the QRS is >120 ms,
discussing with a paediatric cardiologist the possible
discontinuation of the SGA should be seriously
considered.
Guidelines pointed out that routinely prolactin deter-
minations can be avoided in patients without symptoms
(gynecomastia, galactorrhea, and amenorrhea) [17, 18].
However, in our opinion, given the uncertainties about the
effect of a prolonged, albeit asymptomatic, hyperprolacti-
nemia during development, a baseline PRL, a monthly
clinical monitoring of PRL-related symptoms, and periodic
PRL assessments (twice per year) are warranted.
When hyperprolactinemia is persistently high, espe-
cially in youngest patients, a switch to SGAs with
lower risk of hyperprolactinemia (Aripiprazole, Zipra-
sidone, Quetiapine, Olanzapine) should be considered.
In alternative, especially when PRL- related symptoms
are evident, the associations with dopaminergic medica-
tions usually administered for treating hyperprolactine-
mia (bromocriptine, cabergoline), or with low-dose
Aripiprazole, should be considered [90, 91].
Conclusion
Findings from this review highlight the need for a constant,
rigorous and careful monitoring of young patients receiv-
ing SGAs. There is need for long-term studies, aimed to
improve monitoring by all professionals involved in paedi-
atric (physical and mental) health. Only from studies in-
cluding large, consecutive, unselected young patients with
different gender and age ranges, from different sites, may
new information stem to prevent, diminish, or at least
timely detect and deal with SGA-related adverse events. It
was recently shown that the long-term effectiveness of
SGAs in youths needs to be improved, with high rate of
clinicians-decided and patients-decided discontinuation
[92]. A possible improvement strategy is to increase our
knowledge on therapeutic drug monitoring, but to date
empirical information on paediatric populations is scant
[93, 94]. Close paediatrician-child psychiatrist collaboration
should be the first action to achieve this improvement.
Abbreviation
AACAP: American Academy of Child and Adolescent Psychiatry 2011;
CAMESA: Canadian Alliance for Monitoring Effectiveness and Safety of
Antipsychotics in Children; DM2: diabetes mellitus type 2;
ECG: electrocardiogram; EPS: extrapyramidal symptoms; FGA: first generation
antipsychotics; MACKE: massive asymptomatic creatine kinase elevation;
NMS: neuroleptic malignant syndrome; PRL: prolactin; SGA: second
generation antipsychotics.
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Careful and close monitoring/Healthy
lifestyle interventions/Psychoeducation/
if possible switch to another SGA
PRL blood determination Normal PRL Regular monitoring
PRL↑- associated
symptoms
Careful and close monitoring/if possible
lower SGA dose/if possible switch to
another SGA/if possible add Aripiprazole/
discuss with pediatric endocrinolgist to
add on cabergoline or bromocriptine
PRL↑ + associated
symptoms
EPS and other neurological symptoms
monitoring
- EPS Regular monitoring
+ EPS If possible lower dose/if possible add on
anticholinergic or benzodiazepines
NMS symptoms Hospitalization
ECG (if possible and feasible; mandatory
in case of Ziprasidone or positive









Discuss with paediatric cardiologist
about the cardiac safety and the risk
benefit ratio of SGA continuation/
possible SGA discontinuation
Legend: AE adverse effects, DM2 Diabetes Mellitus type 2, ECG electrocardiogram, NMS neuroleptic malignant syndrome, PRL prolactin, EPS
extrapyramidal symptoms
aThe table summarizes findings from the present review (and is inspired by previously published guidelines [17, 18]); it is limited to the AEs reviewed in the
present review; it would represent a guide for clinicians without replacing their clinical judgement
Pisano et al. Italian Journal of Pediatrics  (2016) 42:51 Page 8 of 11
Authors’ contributions
SP and GM conceived the manuscript, wrote the draft of the manuscript and
critically reviewed it. GC, SV, VL, MP, EC, RI, MR, SR, MM, AC, AG, GC, AM, CB
wrote parts of the manuscript, provided comments on the manuscript for
important intellectual content, critically reviewed it. All authors read and
approved the final manuscript.
Author details
1Department of Mental and Physical Health and Preventive Medicine, Child
and Adolescent Neuropsychiatry Division, Second University of Naples, 80131
Naples, Italy. 2Child Neurology and Psychiatry Unit, Center for Rare Diseases,
Department of Pediatrics, Catholic University, Rome, Italy. 3Scientific Institute
IRCCS Eugenio Medea, 23842 Bosisio Parini, Lecco, Italy. 4Unit of Clinical
Pharmacology, CNR Institute of Neuroscience, Department of Biomedical and
Clinical Sciences, L. Sacco University Hospital, Università di Milano, 20157
Milan, Italy. 5Department of Pediatrics, Hospital “F. Veneziale”, Isernia, Italy.
6Unit of Clinical Pharmacology, Department of Biomedical and Clinical
Sciences L Sacco, L. Sacco University Hospital, Università di Milano, 20157
Milan, Italy. 7Faculty of Education Science, University Suor Orsola Benincasa
of Naples, Naples, Italy. 8Campania Regional Centre for Pharmacovigilance
and Pharmacoepidemiology, Department of Experimental Medicine, Second
University of Naples, 80131, Naples, Italy. 9Child Neuropsychiatry, Faculty of
Education, Suor Orsola Benincasa University, Naples, Italy. 10Clinic of Child
and Adolescent Neuropsychiatry, Department of Medicine and Surgery, S.
Giovanni di Dio and Ruggi d’Aragona Hospital, University of Salerno, Fisciano,
Italy. 11IRCCS Stella Maris, Scientific Institute of Child Neurology and
Psychiatry, Calambrone, Pisa, Italy. 12Department of Translational Medical
Sciences, University Federico II of Naples, Via Pansini 5, 80131 Naples, Italy.
Received: 23 February 2016 Accepted: 4 May 2016
References
1. Olfson M, Blanco C, Wang S, Laje G, Correll CU. National trends in the
mental health care of children, adolescents, and adults by office-based
physicians. JAMA Psychiatry. 2014;71:81.
2. Olfson M, King M, Schoenbaum M. Treatment of Young People With
Antipsychotic Medications in the United States. JAMA Psychiatry. 2015;72:
867–74.
3. Zito JM, Safer DJ, de Jong-van den Berg LT, Janhsen K, Fegert JM, Gardner
JF, Glaeske G, Valluri SC. A three-country comparison of psychotropic
medication prevalence in youth. Child Adolesc Psychiatry Ment Health.
2008;2(1):26. doi:10.1186/1753-2000-2-26.
4. Piovani D, Clavenna A, Cartabia M, Bonati M. Psychotropic medicine
prescriptions in Italian youths: a multiregional study. Eur Child Adolesc
Psychiatry. 2016;25(3):235–45.
5. Kreider AR, Matone M, Bellonci C, et al. Growth in the concurrent use of
antipsychotics with other psychotropic medications in Medicaid-enrolled
children. J Am Acad Child Adolesc Psychiatry. 2014;53:960–70.
6. Carton L, Cottencin O, Lapeyre-Mestre M, Geoffroy PA, Favre J, Simon N.
Off-label prescribing of antipsychotics in adults, children and elderly
individuals: a systematic review of recent prescription trends. Curr Pharm
Des. 2015;21(23):3280–97.
7. Pisano S, Catone G, Pascotto A, Gritti A. Second generation antipsychotics in
adolescent anorexia nervosa: a new hypothesis of eligibility criteria. J Child
Adolesc Psychopharmacol. 2014;24:293–5.
8. Masi G, Pisano S, Pfanner C, Milone A, Manfredi A. Quetiapine monotherapy
in adolescents with bipolar disorder comorbid with conduct disorder.
J Child Adolesc Psychopharmacol. 2013;23:568–71.
9. Masi G, Cosenza A, Mucci M, Brovedani P. A 3-year naturalistic study of 53
preschool children with pervasive developmental disorders treated with
Risperidone. J Clin Psychiatry. 2003;64:1039–47.
10. Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and
adolescents. J Clin Psychiatry. 2005;66 suppl 7:29–40.
11. Masi G, Liboni F. Management of schizophrenia in children and adolescents:
focus on pharmacotherapy. Drugs. 2011;71:179–208.
12. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK.
Cardiometabolic risk of second-generation antipsychotic medications
during first-time use in children and adolescents. JAMA. 2009;302:
1765–73.
13. Maayan L, Correll CU. Weight gain and metabolic risks associated with
antipsychotic medications in children and adolescents. J Child Adolesc
Psychopharmacol. 2011;21:517–35.
14. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and
endocrine adverse effects of second generation antipsychotics in children
and adolescents: a systematic review of randomized, placebo controlled
trials and guidelines for clinical practice. Eur Psychiatry. 2011;26:144–58.
15. Safer DJ. A comparison of Risperidone-induced weight gain across the age
span. J Clin Psychopharmacol. 2004;24:429–36.
16. Caccia S. Safety and pharmacokinetics of atypical antipsychotics in children
and adolescents. Paediatr Drugs. 2013;15:217–33.
17. Pringsheim T, Panagiotopoulos C, Davidson J, Ho J. Evidence-based
recommendations for monitoring safety of second generation
antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry.
2011;3:1–2.
18. American Academy of Child and Adolescent Psychiatry. Practice parameter
for the use of atypical antipsychotic medications in children and
adolescents. 2011. Available at https://www.aacap.org/App_Themes/AACAP/
docs/practice_parameters/Atypical_Antipsychotic_Medications_Web.pdf.
Accessed November 17, 2014.
19. Morrato EH, Nicol GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, et al.
Metabolic screening in children receiving antipsychotic drug treatment.
Arch Pediatr Adolesc Med. 2010;164:344–51.
20. Rodday AM, Parsons SK, Mankiw C, Correll CU, Robb AS, Zima BT, et al.
Child and adolescent psychiatrists’ reported monitoring behaviors for
second-generation antipsychotics. J Child Adolesc Psychopharmacol.
2015;25:351–61.
21. Connolly JG, Toomey TJ, Schneeweiss MC. Metabolic monitoring for youths
initiating use of second-generation antipsychotics, 2003–2011. Psychiatr
Serv. 2015;66:604–09.
22. Hampton LM, Daubresse M, Chang HY, Alexander GC, Budnitz DS.
Emergency department visits by children and adolescents for antipsychotic
drug adverse events. JAMA Psychiatry. 2015;72:292–94.
23. Arango C, Giráldez M, Merchán-Naranjo J, Baeza I, Castro-Fornieles J, Alda
JA, et al. Second-generation antipsychotic use in children and adolescents:
a six-month prospective cohort study in drug-naïve patients. J Am Acad
Child Adolesc Psychiatry. 2014;53:1179–90.
24. Noguera A, Ballesta P, Baeza I, Arango C, de la Serna E, González-Pinto A,
et al. Twenty-four months of antipsychotic treatment in children and
adolescents with first psychotic episode: discontinuation and tolerability.
J Clin Psychopharmacol. 2013;33:463–71.
25. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics,
antidepressants and mood stabilizers on risk for physical diseases in people
with schizophrenia, depression and bipolar disorder. World Psychiatry.
2015;14:119–36.
26. Almandil NB, Liu Y, Murray ML, Besag FM, Aitchison KJ, Wong IC. Weight
gain and other metabolic adverse effects associated with atypical
antipsychotic treatment of children and adolescents: a systematic review
and meta-analysis. Paediatr Drugs. 2013;15:139–50.
27. Frighi V. Medical side-effects of antipsychotic agents: hyperprolactinaemia
and metabolic disorders. In: Mortimer AM, McKenna PJ, editors. Therapeutic
strategies in schizophrenia. Oxford: Clinical publishing; 2010. p. 1–19.
28. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of
the first treated episode of psychosis. Arch Gen Psychiatry. 2011;68:609–16.
29. Pringsheim T, Lam D, Ching H, Patten S. Metabolic and neurological
complications of second generation antipsychotic use in children: a
systematic review and meta-analysis of randomized controlled trials.
Drug Safe. 2011;34:651–68.
30. Masi G, Milone A, Veltri S, Iuliano R, Pfanner C, Pisano S. Use of Quetiapine
in children and adolescents. Paediatr Drugs. 2015;17:125–40.
31. de Hoogd S, Overbeek WA, Heerdink ER, Correll CU, de Graeff ER, Staal WG.
Differences in body mass index z-scores and weight status in a Dutch
pediatric psychiatric population with and without use of second-generation
antipsychotics. J Child Adolesc Psychopharmacol. 2012;22:166–73.
32. Ebert T, Midbari Y, Shmilovitz R, Kosov I, Kotler M, Weizman A, et al.
Metabolic effects of antipsychotics in prepubertal children: a retrospective
chart review. J Child Adolesc Psychopharmacol. 2014;24:218–22.
33. Kryzhanovskaya LA, Xu W, Millen BA, Acharya N, Jen KY, Osuntokun O.
Comparison of long-term (at least 24 weeks) weight gain and metabolic
changes between adolescents and adults treated with Olanzapine. J Child
Adolesc Psychopharmacol. 2012;22:157–65.
Pisano et al. Italian Journal of Pediatrics  (2016) 42:51 Page 9 of 11
34. Geller B, Luby JL, Joshi P, Wagner KD, Emslie G, Walkup JT, et al. A randomized
controlled trial of Risperidone, lithium, or divalproex sodium for initial
treatment of bipolar I disorder, manic or mixed phase, in children and
adolescents. Arch Gen Psychiatry. 2012;69:515–28.
35. Kemp DE, Correll CU, Tohen M, Delbello MP, Ganocy SJ, Findling RL, et al.
Associations among obesity, acute weight gain, and response to treatment
with Olanzapine in adolescent schizophrenia. J Child Adolesc Psychopharmacol.
2013;23:522–30.
36. Mankoski R, Stockton G, Manos G, Marler S, McQuade R, Forbes RA,
et al. Aripiprazole treatment of irritability associated with autistic
disorder and the relationship between prior antipsychotic exposure,
adverse events, and weight change. J Child Adolesc Psychopharmacol.
2013;23:572–76.
37. Findling RL, McKenna K, Earley WR, Stankowski J, Pathak S. Efficacy and
safety of Quetiapine in adolescents with schizophrenia investigated in a
6-week, double-blind, placebo-controlled trial. J Child Adolesc
Psychopharmacol. 2012;22:327–42.
38. Findling RL, Pathak S, Earley WR, Liu S, DelBello M. Safety, tolerability, and
efficacy of Quetiapine in youth with schizophrenia or bipolar I disorder: a
26-week, open-label, continuation study. J Child Adolesc Psychopharmacol.
2013;23:490–01.
39. O’Donoghue B, Schäfer MR, Becker J, Papageorgiou K, Amminger GP.
Metabolic changes in first-episode early-onset schizophrenia with second-
generation antipsychotics. Early Interv Psychiatry. 2014;8:276–80.
40. Calarge CA, Nicol G, Schlechte JA, Burns TL. Cardiometabolic outcomes in
children and adolescents following discontinuation of long-term
Risperidone treatment. J Child Adolesc Psychopharmacol. 2014;24:120–29.
41. Wink LK, Early M, Schaefer T, Pottenger A, Horn P, McDougle CJ, et al. Body
mass index change in autism spectrum disorders: comparison of treatment
with Risperidone and Aripiprazole. J Child Adolesc Psychopharmacol.
2014;24:78–82.
42. Pérez-Iglesias R, Martínez-García O, Pardo-Garcia G, Amado JA, Garcia-
Unzueta MT, Tabares-Seisdedos R, et al. Course of weight gain and
metabolic abnormalities in first treated episode of psychosis: the first
year is a critical period for development of cardiovascular risk factors.
Int J Neuropsychopharmacol. 2014;17:41–51.
43. Galling B, Correll CU. Do antipsychotics increase diabetes risk in children
and adolescents? Expert Opin Drug Saf. 2015;14:219–41.
44. Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen H-L, Rickels K. Antipsychotic-
induced insulin resistance and postprandial hormonal dysregulation
independent of weight gain or psychiatric disease. Diabetes. 2013;62:
3232–40.
45. Andrade SE, Lo JC, Roblin D, et al. Antipsychotic medication use among
children and risk of diabetes mellitus. Pediatrics. 2011;128:1135–41.
46. Nielsen RE, Laursen MF, Vernal DL, BiSGAard C, Jakobsen H, Steinhausen HC,
et al. Risk of diabetes in children and adolescents exposed to
antipsychotics: a nationwide 12-year case–control study. J Am Acad Child
Adolesc Psychiatry. 2014;53:971–79.
47. Bobo WV, Cooper WO, Stein CM, Olfson M, Graham D, Daugherty J, et al.
Antipsychotics and the risk of type 2 diabetes mellitus in children and
youth. JAMA Psychiatry. 2013;70:1067–75.
48. Sohn M, Talbert J, Blumenschein K, Moga DC. Atypical antipsychotic
initiation and the risk of type II diabetes in children and adolescents.
Pharmacoepidemiol Drug Saf. 2015;24:583–91.
49. Rubin DM, Kreider AR, Matone M, Huang YS, Feudtner C, Ross ME, et al.
Risk for incident diabetes mellitus following initiation of second-generation
antipsychotics among Medicaid-enrolled youths. JAMA Pediatr. 2015;169:
e150285.
50. Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, et al.
Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics:
A Systematic Review and Meta-analysis. JAMA Psychiatry. 2016;73(3):
247–59. doi:10.1001/jamapsychiatry.2015.2923.
51. Galler A, Bollow E, Meusers M, Bartus B, Näke A, Haberland H, et al. German
Federal Ministry of Education and Research (BMBF) Competence Network
Diabetes Mellitus. Comparison of glycemic and metabolic control in youth
with type 1 diabetes with and without antipsychotic medication: analysis
from the nationwide German/Austrian Diabetes Survey (DPV). Diabetes
Care. 2015;38:1051–57.
52. Pisano S, Gritti A, Catone G, Pascotto A. Antipsychotic-induced dyslipidemia
treated with omega 3 fatty acid supplement in an 11-year-old psychotic
child: a 1-year follow-up. J Child Adolesc Psychopharmacol. 2013;23:139–41.
53. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and
cardiovascular adverse effects associated with antipsychotic drugs.
Nat Rev Endocrinol. 2011;8:114–26.
54. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly
approved antipsychotics on serum prolactin levels: a comprehensive review.
CNS Drugs. 2009;19:403–14.
55. Roke Y, van Harten PN. Boot AM, Buitelaar JK. Antipsychotic medication in
children and adolescents: a descriptive review of the effects on prolactin
level and associated side effects. J Child Adolesc Psychopharmacol.
2009;19:403–14.
56. Dos Santos Júnior A, Henriques TB, de Mello MP, Neto AP, Paes LA,
Torre OH, et al. Hyperprolactinemia in Children and Adolescents with
Use of Risperidone: Clinical and Molecular Genetics Aspects. J Child
Adolesc Psychopharmacol. 2015;25:738–48.
57. de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the Mechanism
of Action of Aripiprazole: Translational Insights into Antipsychotic
Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015;29:
773–99.
58. Masi G, Milone A, Stawinoga A, Veltri S, Pisano S. Efficacy and Safety
of Risperidone and Quetiapine in Adolescents With Bipolar II Disorder
Comorbid With Conduct Disorder. J Clin Psychopharmacol. 2015;35:
587–90.
59. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M. Long-term use of
Risperidone in children with disruptive behavior disorders and
subaverage intelligence: Efficacy, safety, and tolerability. J Child
Adolesc Psychopharmacol. 2006;16:260–72.
60. Dunbar F, Kusumakar V, Daneman D, Schulz M. Growth and sexual
maturation during long-term treatment with Risperidone. Am J Psychiatry.
2004;161:918–20.
61. Etminan M, Carleton B, Brophy JM. Risperidone and Risk of Gynecomastia in
Young Men. J Child Adolesc Psychopharmacol. 2015;25:671–73.
62. Safer DJ, Calarge CA, Safer AM. Prolactin serum concentrations during
Aripiprazole treatment in youth. J Child Adolesc Psychopharmacol. 2013;23:
282–89.
63. Labellarte MJ, Crosson JE, Riddle MA. The relevance of prolonged QTc
measurement to pediatric psychopharmacology. J Am Acad Child Adolesc
Psychiatry. 2003;42:642–50.
64. Kimura G, Kadoyama K, Brown JB, Nakamura T, Miki I, Nisiguchi K, et al.
Antipsychotics-associated serious adverse events in children: an analysis of
the FAERS database. Int J Med Sci. 2015;12:135–40.
65. Blair J, Taggart B, Martin A. Electrocardiographic safety profile and
monitoring guidelines in pediatric psychopharmacology. J Neural Transm
(Vienna). 2004;111:791–15.
66. Jensen KG, Juul K, Fink-Jensen A, Correll CU, Pagsberg AK. Corrected QT
changes during antipsychotic treatment of children and adolescents:
a systematic review and meta-analysis of clinical trials. J Am Acad Child
Adolesc Psychiatry. 2015;54:25–36.
67. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE.
Mechanisms, risk factors, and management of acquired long QT syndrome:
a comprehensive review. ScientificWorldJournal. 2012;2012:212178.
68. Rasimas JJ, Liebelt EL. Adverse Effects and Toxicity of the Atypical
Antipsychotics: What is Important for the Pediatric Emergency Medicine
Practitioner. Clin Pediatr Emerg Med. 2012;13:300–10.
69. Correll CU, Harris J, Figen V, Kane JM, Manu P. Antipsychotic drug
administration does not correlate with prolonged rate-corrected QT interval
in children and adolescents: results from a nested case-control study.
J Child Adolesc Psychopharmacol. 2011;21:365–68.
70. Germanò E, Italiano D, Lamberti M, Guerriero L, Privitera C, D’Amico G,
et al. ECG parameters in children and adolescents treated with
Aripiprazole and Risperidone. Prog Neuro-Psychopharmacol & Biol
Psychiat. 2014;51:23–7.
71. Ho JG, Caldwell RL, McDougle CJ, Orsagh-Yentis DK, Erickson CA, Posey DJ,
et al. The effects of Aripiprazole on electrocardiography in children with
pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2012;
22:277–83.
72. Gulisano M, Calì PV, Cavanna AE, Eddy C, Rickards H, Rizzo R. Cardiovascular
safety of aripiprazole and pimozide in young patients with Tourette
syndrome. Neurol Sci. 2011;32:1213–7.
73. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al.
Comparative efficacy and tolerability of 15 antipsychotic drugs in
schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.
Pisano et al. Italian Journal of Pediatrics  (2016) 42:51 Page 10 of 11
74. Alda JA, Muñoz-Samons D, Tor J, Merchán-Naranjo J, Tapia-Casellas C, Baeza I,
et al. J Child Adolesc Psychopharmacol. 2016 Jan 18. [Epub ahead of print]
75. Correll CU, Lops JD, Figen V, Malhotra AK, Kane JM, Manu P. QT interval
duration and dispersion in children and adolescents treated with
Ziprasidone. J Clin Psychiatry. 2011;72:854–60.
76. Schneider C, Corrigall R, Hayes D, Kyriakopoulos M, Frangou S. Systematic
review of the efficacy and tolerability of Clozapine in the treatment of
youth with early onset schizophrenia. Eur Psychiatry. 2014;29:1–10.
77. Carbon M, Kapoor S, Sheridan E, Al-Jadiri A, Azzo S, Sarkaria T, et al.
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic
Treatment With 5 s-Generation Antipsychotics. J Am Acad Child Adolesc
Psychiatry. 2015;54:718–27.
78. Garcia-Amador M, Merchán-Naranjo J, Tapia C, Moreno C, Castro-Fornieles J,
Baeza I, et al. Neurological Adverse Effects of Antipsychotics in Children and
Adolescents. J Clin Psychopharmacol. 2015;35:686–93.
79. Belvederi Murri M, Guaglianone A, Bugliani M, Calcagno P, Respino M,
Serafini G, et al. Second-generation antipsychotics and neuroleptic
malignant syndrome: systematic review and case report analysis.
Drugs R D. 2015;15:45–62.
80. Neuhut R, Lindenmayer JP, Silva R. Neuroleptic Malignant Syndrome in
Children and Adolescents on Atypical Antipsychotic Medication: A review.
J Child Adolesc Psychopharmacol. 2009;19:4415–22.
81. Masi G, Milone A, Viglione V, Mancini A, Pisano S. Massive Asymptomatic
Creatine Kinase Elevation in youth during antipsychotic drug treatment:
case reports and critical review of the literature. J Child Adolesc
Psychopharmacol. 2014;10:536–42.
82. Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics
result in weight gain: a meta-analysis. PLoS One. 2014;9:e94112.
83. Pramyothin P, Khaodhiar L. Type 2 diabetes in children and adolescents on
atypical antipsychotics. Curr Diab Rep. 2015;15:623. doi:10.1007/s11892-015-
0623-4.
84. Ventriglio A, Gentile A, Baldessarini RJ, Martone S, Vitrani G, La Marca A,
et al. Improvements in metabolic abnormalities among overweight
schizophrenia and bipolar disorder patients. Eur Psychiatry. 2014;29:402–37.
85. Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J. Metformin for
Weight Gain and Metabolic Abnormalities Associated With Antipsychotic
Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin
Psychopharmacol. 2015;35:499–09.
86. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized,
double-blind, placebo-controlled trial of metformin treatment of weight
gain associated with initiation of atypical antipsychotic therapy in children
and adolescents. Am J Psychiatry. 2006;163:2072–69.
87. Romo-Nava F, Alvarez-Icaza González D, Fresán-Orellana A, et al. Melatonin
attenuates antipsychotic metabolic effects: an eight-week randomized,
double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord.
2014;16:410–21.
88. Modabbernia A, Heidari P, Soleimani R. Melatonin for prevention of
metabolic side-effects of olanzapine in patients with first-episode
schizophrenia: randomized double-blind placebo-controlled study.
J Psychiatr Res. 2014;53:133–40.
89. Mostafavi A, Solhi M, Mohammadi MR, et al. Melatonin decreases
olanzapine induced metabolic side-effects in adolescents with bipolar
disorder: a randomized double-blind placebo-controlled trial. Acta Med Iran.
2014;52:734–9.
90. Saranac L, Zivanovic S, Radovanovic Z, Kostic G, Markovic I, Miljkovic P.
Hyperprolactinemia: different clinical expression in childhood. Horm Res
Paediatr. 2010;73:187–92.
91. Chen JX, Su YA, Bian QT, Wei LH, Zhang RZ, Liu YH, et al. Adjunctive
Aripiprazole in the treatment of Risperidone-induced hyperprolactinemia: A
randomized, double-blind, placebo-controlled, dose-response study.
Psychoneuroendocrinology. 2015;58:130–40.
92. Pozzi M, Pisano S, Bertella S, Capuano A, Rizzo R, Antoniazzi S, et al. Persistence
in therapy with Risperidone and Aripiprazole in pediatric outpatients: a two-
year naturalistic comparison. J Clin Psychiatry Accepted in press.
93. Whitney Z, Boyda HN, Procyshyn RM, Elbe D, Black T, Eslami A, et al.
Therapeutic drug levels of second generation antipsychotics in youth: a
systematic review. J Child Adolesc Psychopharmacol. 2015;25:234–45.
94. Pozzi M, Cattaneo D, Baldelli S, Fucile S, Capuano A, Bravaccio C, et al.
Therapeutic drug monitoring of second-generation antipsychotics in
pediatric patients: an observational study in real-life settings. Eur J Clin
Pharmacol. 2016;72:285–93.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Pisano et al. Italian Journal of Pediatrics  (2016) 42:51 Page 11 of 11
